IO Biotech, Inc. (IOBT)
- Previous Close
1.4900 - Open
1.5600 - Bid 1.4200 x 100
- Ask 1.5200 x 100
- Day's Range
1.4200 - 1.5600 - 52 Week Range
0.8160 - 2.6400 - Volume
91,424 - Avg. Volume
136,648 - Market Cap (intraday)
97.504M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
www.iobiotech.comRecent News: IOBT
Performance Overview: IOBT
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IOBT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IOBT
Valuation Measures
Market Cap
96.84M
Enterprise Value
-43.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.78%
Return on Equity (ttm)
-63.29%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-86.08M
Diluted EPS (ttm)
-1.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
143.19M
Total Debt/Equity (mrq)
1.87%
Levered Free Cash Flow (ttm)
-42.19M
Research Analysis: IOBT
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell